A new inhalation treatment for preventing the spread of Covid-19 is potentially far more effective than currently existing versions, according to new research carried out at the University of St Andrews.
ILC Therapeutics, a Scottish biotech company, has announced that its unique synthetic Interferon called Alfacyte™ is more effective at preventing the spread of SARS-CoV-2 in cell culture than other commercially-available Interferons such as Interferon Alpha 2 and Interferon Beta 1a.
Covid-19 tries to slow down the body’s innate Interferon response to viral infection and Alfacyte™ is designed to help accelerate this response and prevent disease progression.